PreSENTIA Hereditary Cancer Tests £550

PreSENTIA hereditary cancer test panels by NIPD Genetics can detect numerous inherited genetic changes (mutations) that could cause cancer in the future.

NIPD Genetics is a leading innovative biotechnology company active in the field of developing, engineering and providing in vitro genetic testing solutions. NIPD Genetics laboratories are accredited by CAP and certified by CLIA and ISO standards and provide  SAFE , ACCURATE  and  RELIABLE  in vitro genetic testing services internationally.   https://www.nipd.com/products/oncology/presentia/

PreSENTIA offers an extensive portfolio of 19 hereditary cancer test panels. Each panel focuses on a set of genes that determine someone’s chances of developing specific cancer in the future. The genetic changes in the genes that could cause cancer are inherited from parents to their children and are present from birth. Knowing that a person carries one of these genetic mutations can help them take preventative measures and plan more informed clinical management. As a result, early detection of cancer can be achieved – which increases the chances of successful treatment – or prevention

Who is this test for?

According to genetic testing guidelines, people who might benefit from genetic testing for hereditary cancers are those that have:

  • Several family members in the same side of the family with cancer
  • Multiple cancers in the same family member
  • Family members with early cancer onset
  • Family members with rare cancer types
  • Family members with an unusual type of cancer (breast cancer in a male)
  • Personal or family history of a hereditary cancer syndrome
  • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
  • History of previous malignancies  

HOW does  PreSENTIA HELP you?

PreSENTIA panels test for numerous genetic changes that are responsible for causing hereditary cancers. If you want to know more about your cancer risks, or if you have been already diagnosed with cancer and you want to know whether your cancer is hereditary, PreSENTIA can help.

  • Targeted cancer monitoring – recommended screening tests at key time intervals to detect cancer early, when treatment is more beneficial
  • Prevention of cancer by prophylactic measures
  • Actionable information for family members that might carry the same gene
  • Improved classification of the disease for better clinical management
  • Drug therapy (chemoprevention)

WHY CHOOSE THE PreSENTIA TEST?

  • Assesses clinically important mutations
  • Ability to select the best panel for you
  • Reliable technology
  • Short turn-around time
  • Safe and easy to perform 

Various PreSENTIA hereditary cancer test panels:  

PreSENTIA Hereditary Breast / Gynaecological cancer panel - £ 575

Hereditary Breast/Gynecological cancer panel tests for numerous germline mutations that could cause Breast, Ovarian or Endometrial cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

No of Genes Tested  : 26

ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, DICER1, EPCAM, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, POLD1, POLE, PTEN, RAD50, RAD51C, RAD51D, SMARCA4, STK11, TP53

Disorders that are related with this Panel : 12

  • Ataxia-telangiectasia syndrome (ATM)
  • Constitutional mismatch repair syndrome (EPCAM, MSH2, MSH6, MLH1, PMS2)
  • DICER 1 syndrome (DICER1)
  • Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2)
  • Hereditary diffuse gastric syndrome (CDH1)
  • Li-Fraumeni syndrome (TP53)
  • Li-Fraumeni syndrome 2 (CHEK2)
  • Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
  • MUTYH-associated polyposis syndrome (MUTYH)
  • Peutz-Jeghers syndrome (STK11)
  • Polymerase proofreading associated syndrome (POLD1, POLE)
  • PTEN hamartoma syndrome (PTEN)

The  genes that are not linked with hereditary cancer syndrome  but are associated with cancer risk, and are also analyzed by this panel:

BARD1, BRIP, MRE11, NBN, PALB2, RAD50, RAD51C, RAD51D, SMARCA4

To Book this PreSENTIA, please Click   BOOK NOW 

PreSENTIA Hereditary Breast / Gynaecological guidelines-based  - £575

Hereditary Breast/Gynecological cancer guidelines-based panel tests for numerous germline mutations that could cause Breast, Ovarian, Endometrial or associated cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

No of Genes Tested   : 19

 ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, PTEN, RAD51C, RAD51D, TP53, STK11

Disorders that are related  with this  Panel : 9

  • Ataxia telangiectasia syndrome (ATM)
  • Constitutional mismatch repair syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
  • Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2)
  • Hereditary diffuse gastric syndrome (CDH1)
  • Li-Fraumeni syndrome (TP53)
  • Li-Fraumeni syndrome 2 (CHEK2)
  • Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
  • Peutz-Jeghers syndrome (STK11)
  • PTEN Hamartoma syndrome (PTEN)

The following genes are not linked with a hereditary cancer syndrome but are associated with cancer risk, and are also analyzed by this panel:

BARD1, BRIP, NBN, PALB2, RAD51C, RAD51D 

To Book this PreSENTIA, please Click   BOOK NOW 

 

PreSENTIA Hereditary Breast High-Risk -  £550

Hereditary Breast High-Risk cancer panel tests for numerous germline mutations that are associated with a high risk for developing Breast, Ovarian, Endometrial or associated cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

No of Genes Tested  : 7

BRCA1, BRCA2, CDH1, PALB2, PTEN, STK11, TP53

Disorders associated with this panel  : 5

  • Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2)
  • Hereditary diffuse gastric syndrome (CDH1)
  • Li-Fraumeni syndrome (TP53)
  • Peutz-Jeughers syndrome (STK11)
  • PTEN hamartoma syndrome (PTEN)

The following genes are not linked with a hereditary cancer syndrome but are associated with cancer risk, and are also analyzed by this panel:

PALB2 

To Book this PreSENTIA, please Click   BOOK NOW 

 

PreSENTIA Hereditary BRCA1/BRCA2 cancer panel - £ 304

 Hereditary BRCA1/BRCA2 cancer panel tests for germline mutations in the BRCA1 and BRCA2 genes that could cause specific cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

No of Genes Tested  :  2

BRCA1, BRCA2

 Disorders associated with this panel: 1

  • Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2)

To Book this PreSENTIA, please Click   BOOK NOW 

 

PreSENTIA Hereditary Colorectal cancer panel -  £ 575

Hereditary Colorectal cancer panel tests for numerous germline mutations that could cause colorectal cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

 No of Genes Tested   :  17

APC, BMPR1A, CDH1, CHEK2, EPCAM, GREM1, MLH1, MSH2, MSH6, MUTYH, PMS2, POLD1, POLE, PTEN, SMAD4, STK11, TP53

Disorders associated with this panel:12

  • Familial Adenomatous Polyposis / Attenuated Familial Adenomatous Polyposis (APC)
  • Li-Fraumeni syndrome (TP53)
  • Li-Fraumeni syndrome 2 (CHEK2)
  • PTEN Hamartoma syndrome (PTEN)
  • Peutz-Jeghers syndrome (STK11)
  • Hereditary diffuse gastric syndrome (CDH1)
  • MUTYH-associated polyposis syndrome (MUTYH)
  • Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM)
  • Polymerase Proofreading Associated syndrome (POLD1, POLE)
  • Hereditary mixed polyposis syndrome (GREM1)
  • Juvenile Polyposis syndrome (SMAD4, BMPR1A)
  • Constitutional Mismatch Repair syndrome (MSH2, MSH6, MLH1, PMS2)

To Book this PreSENTIA, please Click   BOOK NOW 

 

PreSENTIA Hereditary Colorectal High-Risk cancer panel - £ 550

Hereditary Colorectal High-Risk cancer panel tests for numerous germline mutations that could cause colorectal cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

No of Genes Tested   :  10

APC, BMPR1A, EPCAM, MLH1, MSH2, MSH6, MUTYH, PMS2, SMAD4, STK11 

Disorders associated with this panel   :  6

  • Constitutional mismatch repair syndrome (EPCAM, MSH2, MSH6, MLH1, PMS2)
  • Familial Adenomatous Polyposis / Attenuated Familial Adenomatous Polyposis (APC)
  • Juvenile polyposis syndrome (SMAD4, BMPR1A)
  • Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
  • MUTYH-associated polyposis syndrome (MUTYH)
  • Peutz-Jeghers syndrome (STK11)

To Book this PreSENTIA, please Click   BOOK NOW 

 

PreSENTIA Hereditary Colorectal Non-Polyposis cancer panel - £ 550

Hereditary Colorectal High-Risk cancer panel tests for numerous germline mutations that could cause colorectal cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions. 

No of Genes Tested  :  10

APC, BMPR1A, EPCAM, MLH1, MSH2, MSH6, MUTYH, PMS2, SMAD4, STK11 

Disorders associated with this panel    :    6

  • Constitutional mismatch repair syndrome (EPCAM, MSH2, MSH6, MLH1, PMS2)
  • Familial Adenomatous Polyposis / Attenuated Familial Adenomatous Polyposis (APC)
  • Juvenile polyposis syndrome (SMAD4, BMPR1A)
  • Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
  • MUTYH-associated polyposis syndrome (MUTYH)
  • Peutz-Jeghers syndrome (STK11)

To Book this PreSENTIA, please Click   BOOK NOW 

 

PreSENTIA Hereditary Colorectal Polyposis syndrome cancer panel  - £ 550

 Hereditary Colorectal Polyposis cancer panel tests for numerous germline mutations that could cause colorectal cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

No of Genes Tested   :  7 

APC, BMPR1A, MUTYH, POLD1, POLE, SMAD4,STK11

Disorders associated with this panel    :   5

  • Familial Adenomatous Polyposis / Attenuated Familial Adenomatous Polyposis (APC)
  • Juvenile polyposis syndrome (SMAD4, BMPR1A)
  • MUTYH-associated polyposis syndrome (MUTYH)
  • Peutz-Jeghers syndrome (STK11)
  • Polymerase proofreading associated syndrome (POLD1, POLE)

To Book this PreSENTIA, please Click   BOOK NOW 

 

PreSENTIA Hereditary Myelodysplastic syndrome / Leukaemia cancer panel   - £ 625

Hereditary Myelodysplastic syndrome / Leukemia cancer panel tests for numerous germline mutations that could cause blood cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions. 

Who is this test for?

According to genetic testing guidelines, people who might benefit from genetic testing for hereditary myelodysplastic syndromes or leukemias are those that have:

  • Family history of a hereditary cancer syndrome associated with leukemia
  • Personal history of a hereditary cancer syndrome associated with leukemia
  • An identical twin who developed leukemia in the first year of life
  • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility

No of Genes Tested   :  24

ATM, BRCA1, BRCA2, BRIP1, EPCAM, ERCC4, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, MLH1, MSH2, MSH6, PALB2, PMS2, RAD51C, SLX4, TP53

Disorders associated with this panel: 6

  • Ataxia-telangiectasia syndrome (ATM)
  • Constitutional mismatch repair syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
  • Fanconi anemia syndrome (FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, SLX4, ERCC4, BRCA1, BRCA2, BRIP1, PALB2, RAD51C)
  • Hereditary breast & ovarian syndrome (BRCA1 & BRCA2)
  • Li-Fraumeni syndrome (TP53)
  • Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)

To Book this PreSENTIA, please Click   BOOK NOW 

 

PreSENTIA Hereditary Gastric cancer panel - £ 575

 Hereditary Gastric cancer panel tests for numerous inherited germline mutations that could cause gastric (stomach) cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

Who is this test for?

According to genetic testing guidelines, people who might benefit from genetic testing for gastric cancers are those that have:

  • Several family members in the same side of the family with gastric cancer
  • Personal or family history of a hereditary cancer syndrome linked to gastric cancer
  • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility 

No of Genes Tested    :   14

APC, BMPR1A, CDH1, EPCAM, MLH1, MSH2, MSH6, PMS2, SDHB, SDHC, SDHD, SMAD4, STK11, TP53 

Disorders associated with this panel     :  8

  • Familial Adenomatous Polyposis / Attenuated Familial Adenomatous Polyposis (APC)
  • Constitutional mismatch repair syndrome (EPCAM, MSH2, MSH6, MLH1, PMS2)
  • Hereditary diffuse gastric syndrome (CDH1)
  • Hereditary Paraganglioma-Pheochromocytoma syndrome (SDHB, SDHC, SDHD)
  • Juvenile Polyposis syndrome (SMAD4, BMPR1A)
  • Li-Fraumeni syndrome (TP53)
  • Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
  • Peutz-Jeghers syndrome (STK11)

To Book this PreSENTIA, please Click   BOOK NOW 

 

PreSENTIA Hereditary Prostate cancer panel   -   £ 575

Hereditary Prostate cancer panel tests for numerous germline mutations that could cause prostate cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions. 

No of Genes Tested   :   15

ATM, BRCA1, BRCA2, CHEK2, EPCAM, HOXB13, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, PTEN, RAD51D, TP53

Disorders associated with this panel     :    6

  • Ataxia-telangiectasia syndrome (ATM)
  • Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2)
  • Li-Fraumeni syndrome (TP53)
  • Li-Fraumeni syndrome 2 (CHEK2)
  • Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM)
  • PTEN hamartoma syndrome (PTEN)

The following genes are not linked with a hereditary cancer syndrome but are associated with cancer risk, and are also analyzed by this panel:

HOXB13, NBN, PALB2, RAD51D

To Book this PreSENTIA, please Click   BOOK NOW 

 

PreSENTIA Hereditary Pancreatic cancer panel   - £  575

Hereditary Pancreatic cancer panel tests for numerous germline mutations that could cause pancreatic cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

Who is this test for?

According to genetic testing guidelines, people who might benefit from genetic testing for pancreatic cancers are those that have:

  • Several family members in the same side of the family with pancreatic cancer
  • First-degree relative who developed pancreatic cancer before the age of 50
  • Personal or family history of a hereditary cancer syndrome linked to pancreatic cancer
  • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility

No of Genes Tested   :  17

APC, ATM, BRCA1, BRCA2, BMPR1A, CDK4, CDKN2A, (CDKN2Ap16(INK4A), CDKN2Ap14(ARF)), EPCAM, MEN1, MLH1, MSH2, MSH6, PALB2, PMS2, SMAD4, STK11, TP53

 Disorders associated with this panel: 10

  • Ataxia-telangiectasia syndrome (ATM)
  • Constitutional mismatch repair syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
  • Familial Adenomatous Polyposis / Attenuated Familial Adenomatous Polyposis (APC)
  • Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2)
  • Hereditary melanoma-pancreatic cancer syndrome (CDKN2A, CDK4)
  • Juvenile polyposis syndrome (SMAD4, BMPR1A)
  • Li-Fraumeni syndrome (TP53)
  • Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
  • Multiple endocrine neoplasia type 1 (MEN1)
  • Peutz-Jeghers syndrome (STK11)

To Book this PreSENTIA, please Click   BOOK NOW 

 

PreSENTIA Hereditary Renal cancer panel  -  £ 575 

Hereditary Renal cancer panel tests for numerous germline mutations that could cause renal (kidney) cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.  

No of Genes Tested :   13

BAP1, EPCAM, MLH1, MSH2, MSH6, PMS2, PTEN, SDHAF2, SDHB, SDHC, SDHD, TP53, VHL

Disorders associated with this panel: 7

  • BAP1 mutation associated disease (BAP1)
  • Constitutional mismatch repair syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
  • Hereditary Paraganglioma – Pheochromocytoma syndrome (SDHAF2, SDHB, SDHC, SDHD)
  • Li-Fraumeni syndrome (TP53)
  • Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
  • PTEN hamartoma syndrome (PTEN)
  • Von-Hippel Lindau syndrome (VHL)

To Book this PreSENTIA, please Click   BOOK NOW 

 

PreSENTIA Hereditary Skin (Xeroderma-Pigmentosum) cancer panel  -  £ 575

Hereditary Xeroderma Pigmentosum-related cancer panel tests for numerous germline mutations that could cause skin cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

Who is this test for?

According to genetic testing guidelines, people who might benefit from genetic testing for Xeroderma Pigmentosum-related skin cancers are those that have:

  • Family or personal history of a hereditary cancer syndrome associated with skin cancers
  • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility

No of Genes Tested  :   9

DDB2, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, POLH, XPA, XPC

Disorders associated with this panel: 1

  • Xeroderma Pigmentosum syndrome (DDB2, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, POLH, XPA, XPC)

To Book this PreSENTIA, please Click   BOOK NOW 

 

PreSENTIA Hereditary Familial Melanoma cancer panel  - £ 575

Hereditary Familial Melanoma cancer panel tests for numerous germline mutations that could cause familial melanoma skin cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

Who is this test for?

According to genetic testing guidelines, people who might benefit from genetic testing for hereditary melanoma cancers are those that have:

  • At least two first-degree family member who have had metastatic melanoma
  • At least one family member has had multiple melanomas
  • Family or personal history of a hereditary cancer syndrome associated with melanoma
  • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility

No of Genes Tested   :  7

BAP1, BRCA2, CDK4, CDKN2A (CDKN2Ap16(INK4A), CDKN2Ap14(ARF)), PTEN, RB1, TP53

Disorders associated with this panel     :   5

  • BAP1 mutation associated disease (BAP1)
  • Hereditary pancreatic-melanoma syndrome (CDKN2A, CDK4)
  • Li-Fraumeni syndrome (TP53)
  • PTEN hamartoma syndrome (PTEN)
  • Retinoblastoma (RB1)

To Book this PreSENTIA, please Click   BOOK NOW 

 

PreSENTIA Hereditary Paraganglioma/ / Pheochromocytoma cancer panel   -    £  575

Hereditary Paraganglioma / Pheochromocytoma cancer panel tests for germline mutations in numerous genes that could cause Paraganglioma or Pheochromocytoma cancer in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

Who is this test for?

According to genetic testing guidelines, people who might benefit from genetic testing for Paraganglioma or Pheochromocytoma cancers are those that have:

  • Family or personal history of a hereditary cancer syndrome associated with paraganglioma / pheochromocytoma cancers
  • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility 

No of Genes Tested    :  6

RET, SDHAF2, SDHB, SDHC, SDHD, VHL

Disorders associated with this panel :  3 

  • Hereditary Paraganglioma – Pheochromocytoma syndrome (SDHAF2, SDHB, SDHD, SDHC)
  • Multiple endocrine neoplasia type 2 (RET)
  • Von-Hippel Lindau syndrome (VHL)

To Book this PreSENTIA, please Click   BOOK NOW 

 

PreSENTIA Hereditary Parathyroid cancer panel     -      £        550

Hereditary Parathyroid cancer panel tests for germline mutations in the MEN1 gene that could cause parathyroid cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

Who is this test for?

According to genetic testing guidelines, people who might benefit from genetic testing for parathyroid cancers are those that have:

  • At least two first-degree family member who have had parathyroid tumors
  • A personal or family history of a hereditary cancer syndrome associated with parathyroid cancer
  • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility 

No of Genes Tested   :  1

MEN1

Disorders associated with this panel     :    1

  • Multiple endocrine neoplasia type 1 (MEN1)

To Book this PreSENTIA, please Click   BOOK NOW 

 

PreSENTIA Hereditary Thyroid cancer panel  - £ 550

Hereditary Thyroid cancer panel tests for germline mutations in the RET gene that could cause medullary thyroid cancer in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

Who is this test for?

According to genetic testing guidelines, people who might benefit from genetic testing for parathyroid cancers are those that have:

  • At least one first-degree family member who has had thyroid cancer
  • A personal or family history of a hereditary cancer syndrome associated with thyroid cancer
  • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility

No of Genes Tested    :   1

RET

Disorders associated with this panel    :     1

  • Multiple endocrine neoplasia type 2 (RET)

To Book this PreSENTIA, please Click   BOOK NOW 

 

PreSENTIA Hereditary Pan-Cancer panel - £ 950

Hereditary Pan-Cancer panel tests for numerous germline mutations in a total of 62 genes that could cause several cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

Who is this test for?

According to genetic testing guidelines, people who might benefit from genetic testing for hereditary cancers are those that have:

  • Several family members in the same side of the family with cancer
  • Multiple cancers in the same family member
  • Family members with early cancer onset
  • Family members with rare cancer types
  • Family members with an unusual type of cancer (breast cancer in a male)
  • Personal or family history of a hereditary cancer syndrome
  • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
  • History of previous malignancies

 No of Genes Tested   : 62

APC, ATM, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, (CDKN2Ap16(INK4A), CDKN2Ap14(ARF)), CHEK2, DDB2, DICER1, EPCAM, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, GREM1, HOXB13, MEN1, MLH1, MRE11, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, POLD1, POLE, POLH, PTEN, RAD50, RAD51C, RAD51D, RB1, RET, SDHAF2, SDHB, SDHC, SDHD, SLX4, SMAD4, SMARCA4, STK11, TP53, VHL, XPA, XPC

Disorders that are related with this Panel : 24

  •  Ataxia-telangiectasia syndrome (ATM)
  • BAP1 mutation associated disease (BAP1)
  • Constitutional mismatch repair syndrome (EPCAM, MSH2, MSH6, MLH1, PMS2)
  • DICER 1 syndrome (DICER1)
  • Familial Adenomatous Polyposis / Attenuated Familial Adenomatous Polyposis (APC)
  • Fanconi anemia syndrome (FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, SLX4, ERCC4, BRCA1, BRCA2, BRIP1, PALB2, RAD51C)
  • Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2)
  • Hereditary diffuse gastric syndrome (CDH1)
  • Hereditary mixed polyposis syndrome (GREM1)
  • Hereditary melanoma-pancreatic cancer syndrome (CDKN2A, CDK4)
  • Hereditary Paraganglioma – Pheochromocytoma syndrome (SDHD, SDHAF2, SDHC, SDHB)
  • Juvenile polyposis syndrome (SMAD4, BMPR1A)
  • Li-Fraumeni syndrome (TP53)
  • Li-Fraumeni syndrome 2 (CHEK2)
  • Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
  • Multiple endocrine neoplasia type 1 (MEN1)
  • Multiple endocrine neoplasia type 2 (RET)
  • MUTYH-associated polyposis syndrome (MUTYH)
  • Peutz-Jeghers syndrome (STK11)
  • Polymerase proofreading associated syndrome (POLD1, POLE)
  • PTEN hamartoma syndrome (PTEN)
  • Retinoblastoma (RB1)
  • Von-Hippel Lindau syndrome (VHL)
  • Xeroderma Pigmentosum syndrome (DDB2, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, POLH, XPA, XPC)

The  genes that are not linked with  hereditary cancer syndrome  but are associated with cancer risk, and are also analyzed by this panel:

BARD1, MRE11, RAD50, SMARCA4, HOXB13, NBN, RAD51D 

To Book this PreSENTIA, please Click   BOOK NOW 

 

For More information please visit NIPD Genetics

NIPD Genetics is a leading innovative biotechnology company active in the field of developing, engineering and providing in vitro genetic testing solutions. NIPD Genetics laboratories are accredited by CAP and certified by CLIA and ISO standards and provide  SAFE , ACCURATE  and  RELIABLE  in vitro genetic testing services internationally.

https://www.nipd.com/products/oncology/presentia/


HOW ACCURATE IS IT?

  • TARGETED TECHNOLOGY - By focusing only on the genetic changes tested, PreSENTIA is accurate and precise.
  • HIGH READ DEPTH - PreSENTIA analyzes the locations of the genetic changes hundreds of times, making the test results more sensitive and reliable. 

Are you interested in PreSENTIA test? Here’s it how it works

  • CONSULT WITH YOUR HEALTHCARE PROVIDER ON WHICH PANEL IS IDEAL FOR YOU
  • Book an appointment with us 
  • Our health care professionals will collect a buccal swab sample from you
  • The sample will be sent to NIPD's  laboratory
  • The sample will be analyzed at NIPD's laboratory
  • Results will be sent to you within 2-3 weeks

 

F.A.Q

WHAT IS CANCER?

Cancer is the rapid and uncontrollable growth of abnormal cells. It is the second leading cause of death, responsible for 1 out of 6 deaths globally. World Health Organization (WHO) recommends that cancer mortality can be significantly reduced by early detection and proper clinical management of cancers.

HOW DOES CANCER DEVELOP ?
Cancer develops after certain genes that are responsible for keeping our body healthy undergo changes that cause them to become ‘faulty’. A cancer can be: ***. SPORADIC: Mutations in the genes causing cancer accumulate over time due to risk factors like tobacco, viruses (such as HPV), and environmental factors. These mutations cannot be inherited. ***. HEREDITARY: These mutations exist from birth. They run in families and can be passed down from parents to their children *** Inherited genetic mutations make up for 5-10% of all cancers.
What are Germline Mutations?
Germline mutations are changes in the DNA that are inherited from parents to their children. These changes are present from birth in all the cells in the body. People with germline mutations in a cancer gene have a higher chance of developing cancer in their lifetime. If cancer develops due to a germline mutation, it is called hereditary cancer.
What is a Hereditary Screening Test?
A Hereditary Screening test checks if an individual has an inherited gene mutation in a gene with high cancer susceptibility. If you or a family member were diagnosed with hereditary cancer, or a genetic change that is linked to cancer, there's a high chance other members of your family carry the genetic change as well. Each individual could be affected by cancer at different age, with wide range of severity, and by different cancer types.
What is cancer susceptibility and cancer predisposition?

Cancer susceptibility, or predisposition, is the likelihood of being affected by cancer in the future. This depends on an individual’s DNA. There are certain inherited, genetic changes that raise someone’s risk of developing cancer in the future. This is because these changes happen in genes that are responsible for protecting the body from disease, and when they are affected, their protective role halts.

WHO IS THIS TEST FOR ?
 Identifying the genetic change that could cause cancer in the future is useful for people with cancer in their family history, and for people suspected of having a hereditary form of cancer. This knowledge can help with better medical planning, avoiding risk factors and informing family members of their risk. According to genetic testing guidelines* for cancer, people who might benefit from genetic testing are those that have Family members with cancer in the same side of the family , Multiple cancers in the same family member , Family members with early cancer onset , Family members with rare cancer types , A family member that has been diagnosed with a genetic mutation that has cancer susceptibility and Personal or family history of a hereditary cancer syndrome

WHAT ARE ‘HEREDITARY CANCER SYNDROMES’?

Hereditary cancer syndromes are also known as cancer predisposing syndromes, as patients with these syndromes have an elevated risk of developing specific cancers in the future. These conditions occur when genes with critical roles in keeping our body healthy are mutated, causing a variety of symptoms and potentially affecting the quality of life. They can be inherited from one generation to the other.

  • Hereditary cancer syndromes characteristics
  • Multiple cancer types
  • Repeated cancers
  • Young age of cancer onset

If you have cancer in your family history and want to know about your own risk, PreSENTIA can help. By identifying the mutated genes that could cause hereditary cancer syndromes, PreSENTIA can provide information that could help in clinical management. If you have been diagnosed with cancer and have any of the above characteristics, you might also have a hereditary cancer syndrome. Identifying this can help reveal how and why your cancer was caused.

Book now to reserve your spot for Hereditary Cancer Screening Leeds

Book Now